Munich Re Q1 Profit Rises; Backs FY22 Profit View, Lifts Gross Premium Outlook

German reinsurance provider Munich Re Group (0KFE.L) reported Tuesday that its first-quarter profit grew to 608 million euros from last year's 589 million euros.

The operating result totaled 780 million euros, down from 798 million euros a year ago.

Gross premiums written increased substantially by 15.7% to 16.83 billion euros from prior year's 14.55 billion euros.

The annualised return on equity or RoE for the quarter was 9.8%, compared to 10.4% a year ago.

Despite the uncertainties of a challenging environment, Munich Re maintained its annual profit guidance of 3.3 billion euros based on a quarterly profit of more than 600 million euros.

Gross premium is now expected to increase to 64 billion euros in 2022, compared to previous estimate of around 61 billion euros.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT